Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial

• Main Authors: Fabien Zoulim (Author), Claire Fournier (Author), François Habersetzer (Author), Martin Sprinzl (Author), Stanislas Pol (Author), Carla S Coffin (Author), Vincent Leroy (Author), Mang Ma (Author), Heiner Wedemeyer (Author), Ansgar W Lohse (Author), Robert Thimme (Author), Karine Lugardon (Author), Perrine Martin (Author), Bérangère Bastien (Author), Benoit Sansas (Author), Nathalie Adda (Author), Celine Halluard (Author), Kaïdre Bendjama (Author), Maud Brandely (Author), Geneviève Inchauspé (Author)
• Format: Book
• Published: Taylor & Francis Group, 2020-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Treatment of chronic hepatitis B (CHB) typically requires life-long administration of drugs. Cohort and pre-clinical studies have established the link between a functional T-cell-mounted immunity and resolution of infection. TG1050 is an adenovirus 5-based vaccine that expresses HBV polymerase and d...